Andrew P Wright1, Marc S Piper2, Shrinivas Bishu3, Ryan W Stidham3. 1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Loma Linda University Medical Center, Loma Linda, California. 2. Department of Internal Medicine, Division of Gastroenterology, Providence-Providence Park Hospital, Michigan State University College of Human Medicine, Southfield, Michigan. 3. Division of Gastroenterology Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Immune checkpoint inhibitors are used in the treatment of multiple advanced stage cancers but can induce immune-mediated colitis necessitating treatment with immunosuppressive medications. Diagnostic colonoscopy is often performed but requires bowel preparation and may delay diagnosis and treatment. Sigmoidoscopy can be performed rapidly without oral bowel preparation or sedation. AIMS: Characterize the colonic distribution of immune-mediated colitis to determine the most efficient endoscopic approach. METHODS: A systematic review of checkpoint inhibitor-induced colitis case reports and series was conducted in both PubMed and Embase through 3 January 2017. A single centre retrospective chart review of patients who underwent endoscopic evaluation for diarrhoea after treatment with a checkpoint inhibitor (ipilimumab, nivolumab or pembrolizumab) between 1 January 2011 and 3 January 2017 was performed. Clinical, endoscopic and histologic data were collected. RESULTS: A detailed systematic review resulted in 61 studies, in which 226 cases of colitis were diagnosed by lower endoscopy (125 colonoscopy, 101 sigmoidoscopy). Only four patients had isolated findings proximal to the left colon. In our centre, 31 patients had histologic features of checkpoint inhibitor-induced colitis, for which 29 patients had complete data. The left colon was involved in all cases. Sigmoidoscopy would be sufficient to diagnose >98% of reported cases of checkpoint inhibitor-mediated colitis diagnosed by lower endoscopy. CONCLUSIONS: Moderate to severe checkpoint inhibitor-induced colitis involves the left colon in the majority of cases (>98%). Sigmoidoscopy should be the initial endoscopic procedure in the evaluation of this condition.
BACKGROUND: Immune checkpoint inhibitors are used in the treatment of multiple advanced stage cancers but can induce immune-mediated colitis necessitating treatment with immunosuppressive medications. Diagnostic colonoscopy is often performed but requires bowel preparation and may delay diagnosis and treatment. Sigmoidoscopy can be performed rapidly without oral bowel preparation or sedation. AIMS: Characterize the colonic distribution of immune-mediated colitis to determine the most efficient endoscopic approach. METHODS: A systematic review of checkpoint inhibitor-induced colitis case reports and series was conducted in both PubMed and Embase through 3 January 2017. A single centre retrospective chart review of patients who underwent endoscopic evaluation for diarrhoea after treatment with a checkpoint inhibitor (ipilimumab, nivolumab or pembrolizumab) between 1 January 2011 and 3 January 2017 was performed. Clinical, endoscopic and histologic data were collected. RESULTS: A detailed systematic review resulted in 61 studies, in which 226 cases of colitis were diagnosed by lower endoscopy (125 colonoscopy, 101 sigmoidoscopy). Only four patients had isolated findings proximal to the left colon. In our centre, 31 patients had histologic features of checkpoint inhibitor-induced colitis, for which 29 patients had complete data. The left colon was involved in all cases. Sigmoidoscopy would be sufficient to diagnose >98% of reported cases of checkpoint inhibitor-mediated colitis diagnosed by lower endoscopy. CONCLUSIONS: Moderate to severe checkpoint inhibitor-induced colitis involves the left colon in the majority of cases (>98%). Sigmoidoscopy should be the initial endoscopic procedure in the evaluation of this condition.
Authors: Brian I Rini; Mark Stein; Pat Shannon; Simantini Eddy; Allison Tyler; Joe J Stephenson; Lorie Catlett; Bo Huang; Diane Healey; Michael Gordon Journal: Cancer Date: 2010-10-04 Impact factor: 6.860
Authors: L Marthey; C Mateus; C Mussini; M Nachury; S Nancey; F Grange; C Zallot; L Peyrin-Biroulet; J F Rahier; M Bourdier de Beauregard; L Mortier; C Coutzac; E Soularue; E Lanoy; N Kapel; D Planchard; N Chaput; C Robert; F Carbonnel Journal: J Crohns Colitis Date: 2016-01-18 Impact factor: 9.071
Authors: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: F Stephen Hodi; Marcus Butler; Darryl A Oble; Michael V Seiden; Frank G Haluska; Andrea Kruse; Suzanne Macrae; Marybeth Nelson; Christine Canning; Israel Lowy; Alan Korman; David Lautz; Sara Russell; Michael T Jaklitsch; Nikhil Ramaiya; Teresa C Chen; Donna Neuberg; James P Allison; Martin C Mihm; Glenn Dranoff Journal: Proc Natl Acad Sci U S A Date: 2008-02-19 Impact factor: 11.205
Authors: Eduard Cornelis Verschuren; Alfonsus Johannes van den Eertwegh; Janneke Wonders; Rob Michel Slangen; Foke van Delft; Adriaan van Bodegraven; Andra Neefjes-Borst; Nanne Klaas de Boer Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382
Authors: Rob Me Slangen; Alfonsus Jm van den Eertwegh; Adriaan A van Bodegraven; Nanne Kh de Boer Journal: World J Gastrointest Pharmacol Ther Date: 2013-08-06
Authors: James D Lord; Robert C Hackman; Amanda Moklebust; John A Thompson; Celestia S Higano; Deborah Chielens; Gideon Steinbach; George B McDonald Journal: Dig Dis Sci Date: 2009-06-09 Impact factor: 3.199
Authors: Christopher Ma; Rish K Pai; David F Schaeffer; Jonathan Krell; Leonardo Guizzetti; Stefanie C McFarlane; John K MacDonald; Won-Tak Choi; Roger M Feakins; Richard Kirsch; Gregory Y Lauwers; Reetesh K Pai; Christophe Rosty; Amitabh Srivastava; Joanna C Walsh; Brian G Feagan; Vipul Jairath Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469